Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Cash & Equivalents (2023 - 2026)

ArriVent BioPharma has reported Cash & Equivalents over the past 4 years, most recently at $326.4 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $326.4 million for Q1 2026, up 58.83% from a year ago — trailing twelve months through Mar 2026 was $326.4 million (up 58.83% YoY), and the annual figure for FY2025 was $45.5 million, down 34.29%.
  • Cash & Equivalents reached $326.4 million in Q1 2026 per AVBP's latest filing, up from $45.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $326.4 million in Q1 2026 and bottomed at $45.5 million in Q4 2025.
  • Median Cash & Equivalents over the past 4 years was $164.9 million (2023), compared with a mean of $189.5 million.
  • The largest annual shift saw Cash & Equivalents plummeted 62.24% in 2025 before it soared 58.83% in 2026.
  • Over 4 years, Cash & Equivalents stood at $124.3 million in 2023, then plummeted by 44.25% to $69.3 million in 2024, then plummeted by 34.29% to $45.5 million in 2025, then soared by 616.73% to $326.4 million in 2026.
  • Business Quant data shows Cash & Equivalents for AVBP at $326.4 million in Q1 2026, $45.5 million in Q4 2025, and $112.7 million in Q3 2025.